Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised phase II/III trial of definitive chemoradiation with or without cetuximab in oesophageal carcinoma
2006-002241-37Phase 2Completed
- Sponsor
- Velindre University NHS Trust
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of cetuximab in esophageal cancer and Esophagogastric Cancer (2 arms), sponsored by Velindre University NHS Trust. Primary endpoint: Overall Survival. Started Feb 2007; status: completed.
02
Drugs
cetuximab
03
Conditions
esophageal cancerEsophagogastric Cancer
Beyond the preview
Go deeper on 2006-002241-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002241-37.